natgillin/translations-raw huggingface dataset:
In one embodiment, this invention provides a compound represented by the structure of formula X: 
N OH N od, 6. Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom X:
In the second embodiment, the outlet channel 21 is preferably formed by a hose-like protrusion of the actuation member 17 or the like. 
U drugoj izvedbi, izlazni kanal 21 je oblikovan ponajprije pomoću stršećeg elementa sličnog cjevčici za pokretanje 17 ili sličnog.
The pharmaceutical composition of claim 1, comprising droxidopa in combination with entacapone. 
Farmaceutski sastav, prema zahtjevu 1, naznačen je time da sadrži droksidopu u kombinacijama s entakaponom.
The argatroban monohydrate according to claim 3 further comprising the step of drying the obtained crystalline precipitate consisting of argatroban monohydrate. 
Metoda pripreme argatroban monohidrata prema zahtjevu 1 koja sadrži daljnji korak sušenja dobivenog kristaliničnog precipitata argatroban monohidrata.
A process for the preparation of an aminopyrazine derivative according to Formula (I) comprising the step of reacting a derivative according to Formula (viii) with a boronic acid of Formula (iv) under Suzuki reaction conditions to lead to a compound of Formula (I): 
R Postupak pripreme derivata aminopirazina prikazanog Formulom (I) koji obuhvaća korak u kojem derivat Formule (viii) reagira s boratnom kiselinom Formule (iv) u uvjetima Suzuki reakcije, čime nastaje spoj Formule (1):
wherein the alkyl is unsubstituted or substituted with OCH3; and 
pri čemu su alkil, alkenil, alkinil nesupstituirani ili supstituirani s OCH3; a
the scopine is used in the form of its hydrochloride salt; and/or 
skopin se koristi u obliku svoje ugljikovodične soli;
Ulipristal acetate, or any metabolite thereof, for use in treating or preventing a tumour derived from leiomyomata according to claim 10 which is repeated once a year. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 7 u ponavljanju od jednom godišnje.
In a first aspect the invention therefore provides a compound 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1 H- indole-acetic acid, ethyl ester. The compound of the invention may be used in the preparation of a compound of formula: and pharmaceutically acceptable salts and solvates thereof. 
Spoj prema zahtjevu 1 ili 2 naznačen time da je za liječenje bolesti posredovane s CRTh2 gdje je spoj prema formuli (1) odabran od: 5-(acetilamino)-3-[(4-klorofenil)tio]-2-metil-12-indol-1-octene kiseline;
heteroaryl optionally substituted with a C1-C10 alkyl group(s), -SO2R43, C1-C10 alkylthio optionally substituted with a halogen atom(s), 
heteroarila, izborno supstituiranog s jednom ili više C1-C10 alkilnih skupina, -SO2R43, C1-C10 alkiltio, izborno supstituiranog s jednim ili više atoma halogena,
The method according to claim 10, wherein the antibiotic resistant bacteria is daptomycin resistant Staphylococcus aureus, daptomycin resistant Enterococcus faecium, daptomycin resistant Enterococcus faecalis, methicillin resistant Staphylococcus aureus, or a mixture of bacteria comprising at least one of the antibiotic resistant bacteria. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što su bakterije otporne na antibiotike Staphylococcus aureus otporan na daptomicin, Enterococcus Jfaecium otporan na daptomicin, Enterococcus faecalis otporan na daptomicin, Staphylococcus aureus otporan na meticilin, ili smjesa bakterija koja sadrži najmanje jednu od bakterija otpornih na antibiotike.
The bispecific antibody or antibody fragment thereof according to one of the claims 1 to 6 comprising a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. Use of the bispecific antibody or antibody fragment of any one of the claims 1 to 7 or 16 in research or diagnostic applications. 
Uporaba protutijela ili fragmenta protutijela prema bilo kojem od zahtjeva 1 do 5 naznačena time da je za istraživanje ili in vitro dijagnostičke primjene, pri čemu navedeno protutijelo ili fragment protutijela sadrži oznaku kao što je radioaktivna oznaka, fluorofora, kromofora, sredstvo za slikanje ili metalni ion.
The 5-fluorouracil derivative or a salt thereof according to claim 1 or 2, wherein R1 represents a hydrogen atom, an allyl group, a benzyl group, an aliphatic acyl group, an aromatic acyl group, or an alicyclic acyl group, R2 represents a lower alkoxymethyl group in which the lower alkoxy moiety has 1 to 6 carbon atoms or a tetrahydrofuranyl group, X represents a carbon atom or a nitrogen atom, and Y represents a fluorine atom or a chlorine atom. 
O . Derivat 5-fluorouracila ili njegova sol, prema zahtjevu 1 ili 2, naznačen time, da R! predstavlja atom vodika, alil-skupinu, benzil-skupinu, alifatsku acil-skupinu, aromatsku acil-skupinu, ili alicikličku acil-skupinu, R7 predstavlja nižu alkoksimetil-skupinu u kojoj niži alkoksi-dio skupine ima od jednog do šest atoma ugljika, ili tetrahidrofuranil-skupinu, X predstavlja atom ugljika ili atom dušika, a Y predstavlja atom fluora ili atom klora.
A method of preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; wherein the method comprises: treating a compound of formula (7): or a pharmaceutically acceptable salt thereof, with a base under suitable conditions to form a compound of formula (8): or a pharmaceutically acceptable salt thereof; and 
\ / CF3 ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (1), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese. Postupak u skladu s patentnim zahtjevom 1, koji se dodatno sastoji u dobivanju spoja formule (7), naznačen time što se postupak sastoji u obradi spoja formule (6):
It is further appreciated that when the GPR119 agonist and the DPP-IV inhibitor are in separate doseage forms, GPR119 agonist and DPP-IV inhibitor can be administered by different routes. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je agonist humanog GPR119, te DPP-IV inhibitor je inhibitor humanog DPP-IV.
The compounds of embodiment 1 wherein R2 is a substituent selected from the group consisting of hydrogen and C1-4alkyl. 
Spoj prema zahtjevu 1 naznačen time da R* je supstituent izabran iz skupine koju čine vodik i Cualkil.
After stirring for 72 hours the reaction mixture was cooled to -10 °C and stirred for another hours. 
Nakon miješanja tijekom 72 sata reakcijska smjesa je ohlađena na -10 "C i miješana idućih sati.
A method of expressing an antigenic molecule or a part thereof on the surface of a cell, comprising contacting said cell with said antigenic molecule and a compound as defined in claim 1, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent of the compound, wherein said antigenic molecule is released into the cytosol of the cell and the antigenic molecule or a part thereof of sufficient size to stimulate an immune response is presented on the cell's surface. 
Postupak eksprimiranja in vitro ili ex vivo antigenske molekule ili njezinog dijela na površini stanice, naznačen time što se sastoji u stavljanju u kontakt navedene stanice s navedenom antigenskom molekulom i spojem u skladu s bilo kojim od patentnih zahtjeva 1 do 5, te ozračivanju stanice svjetlom valne duljine koja djelotvorno aktivira fotosenzibilizirajuće sredstvo spoja, gdje se navedenu antigensku molekulu otpušta u citosol stanice, a antigensku molekulu ili njezin dio dovoljno velik za stimuliranje imunosnog odgovora se predočava na površini stanice.
The solution was heated to refluxed for 15 min. 
Otopina je zagrijavana do refluksa kroz 15 minuta.
The compound for use of claim 11, wherein the parasitic disease is malaria, babesiosis, trypanosomiasis, leishmaniasis, toxoplasmosis, meningoencephalitis, keratitis, amebiasis, giardiasis, cryptosporidiosis, isosporiasis, cyclosporiasis, microsporidiosis, ascariasis, trichuriasis, ancylostomiasis, strongyloidiasis, toxocariasis, trichinosis, lymphatic filariasis, onchocerciasis, filariasis, schistosomiasis, or dermatitis caused by animal schistosomes. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da parazitska bolest je malarija, babezioza, tripanosomijaza, lišmanijaza, toksoplazmoza, meningoencefalitis, keratitis, amebijaza, giardijaza, kriptosporidioza, izosporijaza, ciklosporijaza, mikrosporidioza, askarijaza, trihurijaza, ankilostomijaza, strongiloidijaza, toksokarijaza, trihinoza, limfatična filarijaza, ili dermatitis uzrokovan životinjskim shistosomama.
a plunger (2) attached to the handle (3), the second end of the insertion tube being attached to the slider (5) and further comprising: 
- < klip(2) spojen za držač (3), drugi kraj cjevčice za umetanje spojen je za klizač (5).
The process of the invention includes: 
Datum podnošenja europske prijave patenta:
A pharmaceutical combination of Claim 28 wherein the PPARa/Y dual agonists are selected from MK-767/KRP-297, tesaglitazar and muraglitazar. 
Farmaceutski sastav Zahtjeva 28, naznačen time, da su PPAR a/y dvojni agonisti odabrani od MK-767/KRP-297, tesaglitazar i muraglitazara.
Formulation of the cheese milk: 
Broj objave europskog patenta:
A system according to claim 9, characterised in that the LBAS GT (40) is connected to a LBAS Service (50) that is connected to an interface for managing and controlling the system, and where the interface is used for selecting type of alert message and the geographical area to where the messages are to be sent. 
Sustav prema zahtjevu 9, naznačen time da je LBAS GT (40) povezan s LBAS servisom (50) koji je povezan s sučeljem za upravljanje i nadzor postupka, te gdje se sučelje koristi za odabir vrste poruke upozorenja i zemljopisnog područja gdje se trebaju slati poruke
Tricloroacetic acid (90 mg, 0.55 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. 
Dodana je trifiloracetična kiselina (90 mg, 0,30 mmol) i reakcijska smjesa je miješana na sobnoj temperaturi tijekom 16 sati.
they are both oriented on the same side of the ring). 
one su obje orijentirane na istoj strani prstena).
A treated seed comprising a composition of claim 1 in an amount of from about 0.0001 to 1% by weight of the seed before treatment. 
Tretirano sjeme koje sadrži kompoziciju prema bilo kojem od patentnih zahtjeva 1 do 8 u količini od oko 0.0001 do 1 težinskih % sjemena prije tretmana.
a butt end (101) adjoining the at least two straps such that the nose end and the butt end are separated by the at least two straps, wherein the butt end comprises at least one concave contour along an outside surface of the butt end, the outside surface being a surface along the butt end opposite the nose end that extends from a top surface of the at least one top strap to a bottom surface of the at least one bottom strap, characterised in that the butt end comprises two concave contours (110), the two concave contours comprising a top concave contour located along a top portion of the outside surface and a bottom concave contour located along a bottom portion of the outside surface. 
stražnji kraj (101) graniči s barem dvije spojne trake, tako da su prednji i stražnji kraj razdvojeni s najmanje dvije spojne trake, pri čemu stražnji kraj sadrži najmanje jednu konkavnu konturu po vanjskoj površini stražnjeg kraja, a vanjska površina je površina duž stražnjeg kraja nasuprot prednjeg kraja koji se proteže od gornje površine barem jedne gornje spojne trake do donje površine barem jedne donje spojne trake, naznačen time, da se stražnji kraj sastoji od dvije konkavne konture (110), a dvije konkavne konture imaju gornju konkavnu konturu koja se nalazi uz gornji dio vanjske površine i donju konkavnu konturu smještenu duž donjeg dijela vanjske površine.
Commun., 54, 3294-3338 also discloses various derivatives of diphenyl sulphides, “phenyl-thio-benzylamines” as antidepressants. 
54, 3294-3338 Također opisuje razne derivate difenil sulfida "fenil-tio-ben-zilamina" kao antidepresive.
Advantageously, the carboxylic acid metal salt is aluminum acetate, zinc acetate, magnesium acetate, magnesium succinate, aluminum adipate, magnesium adipate, magnesium citraconate, aluminum phthalate, magnesium phthalate, aluminum citrate, zinc citrate, magnesium citrate, magnesium trimellitate or magnesium 1,2,3,4-butanetetracarboxylate. 
Proizvod sukladno zahtjevima 1 do 4, naznačen time da je metalna sol polikarboksilne kiseline magnezijev sukcinat, aluminijev adipat, magnezijev adipat, magnezijev citrakonat, aluminijev ftalat, magnezijev ftalat, aluminijev citrat, cinkov citrat, magnezijev citrat, magnezijev trimelitat, magnezijev 1,2,3,4-butantetrakarboksilat.
A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 together with at least one pharmaceutical carrier and/or excipient. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1 ili 2, kao i, u najmanju ruku, jednu farmaceutsku podlogu i/ili pomoćnu tvar.
subsequent reduction of the corresponding enamines with hydrides in acetic acid, to yield the corresponding saturated pro-ducts; possible salification of the compound obtained in stage b). 
HR P20080682 T3 b) naknadna redukcija odgovarajućih enamina s hidridima u octenoj kiselini, kako bi se dobilo odgovarajuće zasićene produkte; c) moguće prevođenje u sol spoja dobivenog u stupnju b)
Use of the binder according to claims 10 - 13 for impregnating mineral fibers, preferably glass fibers or basalt fibers. Mineral fibers bonded by a cured binder according to any one of claims 10-13. 
Uporaba veziva u skladu s patentnim zahtjevima 10 - 13, naznačena time, da se koristi za impregniranje mineralnih vlakna, posebice staklenih vlakna ili bazaltnih vlakna.
Specifically, the invention provides compounds selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine:
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 wherein it is to be administered by oral route. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje oralnim putem.
The process according to anyone of claims 1-6, wherein the water-soluble coating mixture comprises, further to the filming substance, additives for the stabilization of the coating mixture selected from the group consisting of talc, mannitol, soy lecithin, microcrystalline cellulose and stearic acid. 
Postupak prema bilo kojem od patentnih zahtjeva 1-5, naznačen time što smjesa za oblaganje koja je topiva u vodi sadrži, pored supstance za formiranje filma, aditive za stabilizaciju smjese za oblaganje izabrane iz grupe koja se sastoji od talka, manitola, sojinog lecitina, mikrokristalne celuloze i stearinske kiseline.
Pharmaceutical for use in the treatment of inflammatory diseases containing R,R-glycopyrrolate, rolipram and budesonide or their physiologically acceptable salts 
Farmaceutski proizvod, naznačen time, da se koristi za liječenje upalnih oboljenja, a sadrži R,R-glikopirolar, rolipram i budesonid ili njihove fiziološke prihvatljive soli.
subjecting the co-product stream to a first separation stage to recover a first stream rich in the unfermented organic material and a second stream rich in the fermentation agent suspended in the aqueous solution; and 
(iv) podvrgavanje struje ko-proizvoda prvoj fazi odvajanja da se dobije prva struja bogata s nefermentiranim organskim materijalom i druga struja bogata s fermentacijskim sredstvom suspendiranim u vodenoj otopini; i
The sliding door system of any of claims 3 - 5, wherein the support system is one or more conveyor belts each configured to support a distinct wheel of the vehicle. 
Sustav kliznih vrata prema zahtjevu 1, gdje je pokretni sustav jedna ili više pokretnih traka (714), (716), od kojih je svaka napravljena da podupire različiti kotač.
a Cas9 protein that comprises a mutation in a RuvC and/or an HNH domain; and 
polipeptid Cas9, ili polinukleotid koji kodira navedeni polipeptid Cas9; i/ili
wherein R1 is hydrogen or a nitrogen protecting group and R6 is a leaving group, with an activated biphenylic compound. 
(11) gdje RI je vodikova ili dušikova zaštitna skupina i R6 je izlazna skupina, s aktiviranim bifenilnim spojem.
R3003 (SEQ ID NO: 4) was the most potent polypeptide tested, with a Ki value of 9.54 nM. 
Polipeptid u skladu s patentnim zahtjevom 1, pri čemu je navedeni polipeptid SEQ ID NO: 177.
The composition of the present invention is also used as a prophylactic. 
Sastav za upotrebu temeljem zahtjeva 1, pri čemu se sastav koristi kao profilaktik.
The compounds of the present invention may be employed in combination with anti-hypertensive agents. 
Spojevi prikazanog izuma mogu se koristiti u kombinaciji sa lijekovima protiv visokog tlaka.
The process according to claim 1, wherein step (2) of the process is performed in the presence of a transition metal compound, and wherein the transition metal compound is a palladium compound. 
Postupak prema zahtjevu 1, u kome se korak (2) postupka provodi u prisutnosti spoja prijelaznog metala, 1 pri čemu je spoj prijelaznog metala paladijev spoj.
The computer program product of claim 8, wherein the transaction begin instruction initiates a nonconstrained transaction, the nonconstrained transaction being an outermost transaction. 
Računalni programski proizvod u skladu s patentnim zahtjevom 8, naznačen time što uputa o početku transakcije započinje neograničenu transakciju, gdje je neograničena transakcija krajnja transakcija.
drug, which is risperidone present as particles having a particle size distribution as follows: not more than 10% of the total volume of drug particles is less than 10 microns in size, not more than 10% of the total volume of drug particles is greater than 225 microns in size, and the d0.5 of the size distribution is in the range of about 60-130 microns; and 
Manje od 10% čestica je manje od 10 mikrona; manje od 10% čestica većih od 225 mikrona, a vrijednost dO,5 je u rasponu od 60-130 mikrona. Sastav u skladu s patentnim zahtjevom 1, naznačen time što je otapalo dimetilsulfoksid (DMSO). Sastav u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je omjer mase lijeka/polimera otprilike 33%.
In mouse microsomes ST2472 was metabolized almost exclusively to M2 (FIG. 3). 
U mikrosomima miša 512472 gotovo se isključivo metabolizirao u M2 (Slika 3).
and R5, taken together with the carbon atom to which they are attached to, may form a substituted or unsubstituted 3- to 7- membered carbocyclic or heterocyclic ring; or any one of R4 and R5 in X and any one of R4 and R5 in Y combined together, when they are attached to carbon atoms, may form a 4- to 7- membered substituted or unsubstituted heterocyclic ring in order to give a bicyclic heterocyclic ring; 
Rx i Rs, uzeti zajedno sa atomom ugljika za koji su vezani, mogu formirati supstituiran ili nesupstituiran 3- do 7-člani karbociklični ili heterociklični prsten; ili bilo koji od R4 1 Rs u X i bilo koji od Ru i Rs u Y kombinovani zajedno, kada su vezani za atome ugljika, mogu formirati 4- do 7- člani supstituirani ili nesupstituirani heterocilični prsten u cilju dobijanja bicikličnog heterocikličnog prstena; prsten D je izabran od
The lid of claim 10, wherein the at least one of the stacking male parts is disposed on a narrow side of the lid. 
Poklopac prema najmanje jednom od zahtjeva 1 do 7, naznačen time što su muški dijelovi za slaganje (25) koji su predviđeni s udubljenjem (33) smješteni na uskoj strani poklopca (2, 2').
An inhaler according to claim 1 or 2, wherein when in use the outer side surface of the manifold and the peeling edge (119) are arranged so as to define a gap sufficient to enable the cover sheet (7) to pass therethrough, said gap being less than or equal to about 1 mm, preferably less than or equal to about 0.8 mm, more preferably less than or equal to about 0.4 mm. 
Inhalator u skladu s patentnim zahtjevom 1 ili 2, pri čemu su, kada je u uporabi, vanjska postranična površina cjevovoda i rub za odvajanje (119) postavljeni tako da određuju procjep dovoljan za omogućavanje prolaska pokrovnoj ploči (7), navedeni procjep je manji od ili jednak približno 1 mm, poželjno manji ili jednak približno 0.8 mm, još poželjnije manji ili jednak približno 0.4 mm.
A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, for use in a method of treating allergy or asthma,. 
Spoj prema bilo kojem od zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku tretmana alergije ili astme.
According to some embodiments of the invention, the culturing of the cells in the 3D culture is effected under perfusion. According to some embodiments of the invention, the culturing conditions of the three-dimensional culture comprise an adherent material selected from the group consisting of a polyester and a polypropylene. 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 1 7 do 10, naznačeni time što uvjeti uzgoja u navedenoj trodimenzionalnoj kulturi uključuju adherentni materijal, koji se bira iz skupine koju čine poliester i polipropilen.
Het1 represents 3-pyridyl, represents hydroxyl, 
naznačen time da Het1 predstavlja 3-piridil,
removing the amino protecting group R4 and subsequent forming an amine salt of formula XII wherein R1 and R3' are as above and X- is an acid anion; 
R gdje je R' esterska zaštitna skupina, a R* i R" su kao gore; bl) uklanjanje amino zaštitne skupine R* i naknadno formiranje soli amina formule XII
at least two of the bands have a different width. 
najmanje dvije trake imaju različitu širinu.
Table 1: Representative Compounds of Formula (I) 
PATENTNI ZAHTJEVI L Spoj formule (I)
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
protection of the hydroxy groups at the 2'- and 3'- positions of the glucuronic acid units of the compound obtained in the previous step by reaction with an anhydride of formula (R2CO)2O in which R2 is selected from methyl, ethyl or propyl, in the presence of pyridine or an organic tertiary base selected from triethylamine or triisopropylamine and of 4-dimethylaminopyridine (DMAP), to give a compound in which the repeating disaccharide unit present in chondroitin has the formula II in which R, R1 and R2 are as defined above; 
zaštita hidroksi skupina u položajima 2' i 3' jedinica glukuronske kiseline spoja dobivenog u prethodnom koraku reakcijom s anhidridom formule (R2CO)2O u kojoj je R2 odabran od metila, etila ili propila, u prisutnosti piridina ili organske tercijarne baze odabrane od trietilamina ili triizopropilamina te 4-dimetilaminopiridina (DMAP), pri čemu nastaje spoj u kojem ponavljajuća jedinica disaharida prisutna u kondroitinu ima formulu II u kojoj R, R1 i R2 jesu kao što je gore definirano;